15 assets in Cervical Adenocarcinoma

Therapeutic assets addressing Cervical Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii Cervical Adenocarcinoma	Uganda Cancer Institute	P2	BB (64)
e7 tcr-t cells Cervical Adenocarcinoma	Christian Hinrichs	P2	B (58)
Ipilimumab Cervical Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Cervical Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Rifaximin Cervical Adenocarcinoma	Mansoura University	P1/2	CC (47)
[225Ac]Ac-AKY-1189 Cervical Adenocarcinoma	Aktis Oncology, Inc.	P1	CC (43)
[64Cu]Cu-AKY-1189 Cervical Adenocarcinoma	Aktis Oncology, Inc.	P1	CC (43)
ava6103 Cervical Adenocarcinoma	Avacta Life Sciences Ltd	P1	CC (43)
Tsc-200-A0201 Cervical Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-201-B0702 Cervical Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-202-A0201 Cervical Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-203-A0201 Cervical Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0101 Cervical Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0201 Cervical Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-C0702 Cervical Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (41)